• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 54-68 of 227,272 results

45 Motion: Joint Motion to Terminate

Document IPR2019-00739, No. 45 Motion - Joint Motion to Terminate (P.T.A.B. May. 29, 2020)
Statement of Precise Relief Requested Pursuant to 35 U.S.C. § 317(a) and as authorized by the Board on May 27, 2020, Petitioner Amgen Inc. (“Amgen”) and Patent Owner Alexion Pharmaceuticals, Inc. (“Alexion”) jointly request termination of the Inter Partes Review of U.S. Patent No. 9,725,504 (“the ’504 patent”), Case No. IPR2019- 00739.
Argument The parties have executed a settlement agreement that resolves all of their disputes concerning the ’504 patent, expressly including the present Inter Partes Review (IPR).
Further, maintaining this proceeding would contradict the Congressional goal to establish a more efficient and streamlined patent system that limits unnecessary and counterproductive litigation costs.
Submitted concurrently herewith is a joint request to file the settlement agreement as business confidential information pursuant to 35 U.S.C. § 317(b) and § 42.74(c).
CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e)) I certify that the above-captioned “Joint Motion To Terminate Proceeding Pursuant To 35 U.S.C. § 317 and 37 C.F.R. § 42.74” was served in its entirety on May 29, 2020, upon the following counsel for Patent Owner via electronic mail: Gerald J. Flattmann, Jr. Vanessa Y.
cite Cite Document
Analyze

45 Motion: Joint Motion to Terminate

Document IPR2019-00741, No. 45 Motion - Joint Motion to Terminate (P.T.A.B. May. 29, 2020)
Log in to see more
cite Cite Document
Analyze

47 Other Not for motions: Exhibit List

Document IPR2019-00741, No. 47 Other Not for motions - Exhibit List (P.T.A.B. May. 29, 2020)

cite Cite Document
Analyze

46 Motion: Joint Motion to File Settlement as BCI

Document IPR2019-00739, No. 46 Motion - Joint Motion to File Settlement as BCI (P.T.A.B. May. 29, 2020)
Log in to see more
cite Cite Document
Analyze

43 Reply: Petitioners Reply ISO Motion to Exclude

Document IPR2019-00740, No. 43 Reply - Petitioners Reply ISO Motion to Exclude (P.T.A.B. May. 22, 2020)

cite Cite Document
Analyze

43 Reply: Petitioners Reply ISO Motion to Exclude

Document IPR2019-00739, No. 43 Reply - Petitioners Reply ISO Motion to Exclude (P.T.A.B. May. 22, 2020)

cite Cite Document
Analyze

43 Reply: Petitioners Reply ISO Motion to Exclude

Document IPR2019-00741, No. 43 Reply - Petitioners Reply ISO Motion to Exclude (P.T.A.B. May. 22, 2020)

cite Cite Document
Analyze

MOTOR VEHICLE CONTROLLER, METHOD FOR MONITORING A MOBILE INTER...

Docket 16/309,753, U.S. Patent Application (Dec. 13, 2018)

cite Cite Docket
Analyze

Motor Vehicle With Radio Modem, Radio Modem, and Method for Exchanging Com...

Docket 16/309,748, U.S. Patent Application (Dec. 13, 2018)

cite Cite Docket
Analyze

PROCESS FOR THE IDENTIFICATION OF COMPOUNDS FOR TREATING CANCER

Docket 16/216,714, U.S. Patent Application (Dec. 11, 2018)

cite Cite Docket
Analyze

METHOD FOR ASSISTING A DRIVER

Docket 16/308,280, U.S. Patent Application (Dec. 7, 2018)

cite Cite Docket
Analyze

42 Opposition: Patent Owner¿¿¿s Opposition To Petitioners Motion To Exclude Evid...

Document IPR2019-00740, No. 42 Opposition - Patent Owner¿¿¿s Opposition To Petitioners Motion To Exclude Evidence Under 37 CFR 4264c (P.T.A.B. May. 15, 2020)

cite Cite Document
Analyze

42 Opposition: Patent Owner¿¿¿s Opposition To Petitioners Motion To Exclude Evid...

Document IPR2019-00741, No. 42 Opposition - Patent Owner¿¿¿s Opposition To Petitioners Motion To Exclude Evidence Under 37 CFR 4264c (P.T.A.B. May. 15, 2020)

cite Cite Document
Analyze

TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODY

Docket 16/306,285, U.S. Patent Application (Nov. 30, 2018)

cite Cite Docket
Analyze

USE OF ANTI-PD-1 ANTIBODY IN THE TREATMENT OF PATIENTS WITH COLORE...

Docket 16/306,290, U.S. Patent Application (Nov. 30, 2018)

cite Cite Docket
Analyze
<< 1 2 3 4 5 6 7 8 ... >>